Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal

被引:7
作者
Sarrazin, Christoph [1 ,2 ,3 ]
Boesecke, Christoph [4 ,5 ]
Golsabahi-Broclawski, Solmaz [6 ]
Moog, Gero [7 ]
Negro, Francesco [8 ,9 ,10 ]
Silaidos, Carmina [11 ]
Patel, Polly [12 ]
Lohmann, kristina [11 ]
Spinner, Christoph D. [13 ,14 ]
Walcher, Stephan [15 ]
Wedemeyer, Heiner [16 ,17 ]
Woerns, Marcus-Alexander [18 ,19 ]
机构
[1] Goethe Univ Hosp Frankfurt, Dept Internal Med, Frankfurt, Germany
[2] Goethe Univ Hosp Frankfurt, St Josefs Hosp Wiesbaden, Liver Ctr, Frankfurt, Germany
[3] Goethe Univ Hosp Frankfurt, Viral Hepatitis Res Grp, Frankfurt, Germany
[4] Univ Hosp Bonn, Dept Med 1, Bonn, Germany
[5] German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Bonn, Germany
[6] Med Inst Transcultural Med, Bielefeld, Germany
[7] Gastroenterol Praxis Marienkrankenhaus, Kassel, Germany
[8] Geneva Univ Hosp, Div Gastroenterol, Geneva, Switzerland
[9] Geneva Univ Hosp, Div Hepatol, Geneva, Switzerland
[10] Geneva Univ Hosp, Div Clin Pathol, Geneva, Switzerland
[11] AbbVie Deutschland GmBH Co KG, Wiesbaden, Germany
[12] AbbVie Inc, N Chicago, IL USA
[13] Tech Univ Munich, Univ Hosp Rechts Isar, Sch Med, Dept Internal Med 2, Munich, Germany
[14] German Ctr Infect Res DZIF, Partner Site Munich, Munich, Germany
[15] CONCEPT, Ctr Addict Med, Munich, Germany
[16] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[17] Leberstiftungs GmbH Deutschland, Hannover, Germany
[18] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 1, Mainz, Germany
[19] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Cirrhosis Ctr Mainz CCM, Mainz, Germany
关键词
barriers; elimination; Germany; Hepatitis C; high-risk groups; DIRECT-ACTING ANTIVIRALS; INJECT DRUGS; HCV; INFECTION; PREVALENCE; PEOPLE; RISK; EPIDEMIOLOGY; MANAGEMENT; EFFICACY;
D O I
10.1002/hsr2.290
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Hepatitis C virus (HCV) affects over 70 million people globally, with an estimated 399 000 HCV-related deaths in 2016. The World Health Organization (WHO) has set a goal to eliminate HCV by 2030. Despite the availability of direct-acting antivirals-highly effective and well-tolerated therapies for HCV-many patients infected with HCV in Germany have not initiated treatment, including a majority of those who are aware of their positive diagnosis. Barriers to screening, diagnosis, and treatment are major factors taking many countries off track for HCV elimination by 2030. Identifying country-specific barriers and challenges, particularly in at-risk populations such as people who inject drugs or men who have sex with men, has the potential to create tailored programs and strategies to increase access to screening or treatment and engage at-risk populations. This review aims to report the current steps toward HCV elimination in Germany, the country-specific barriers and challenges that will potentially prevent reaching the 2030 HCV elimination goal and describe good practice examples to overcome these barriers.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Hepatitis C Virus Treatment in Children: A Challenge for Hepatitis C Virus Elimination
    El-Sayed, Manal H.
    Indolfi, Giuseppe
    SEMINARS IN LIVER DISEASE, 2020, 40 (03) : 213 - 224
  • [32] Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination
    Lim, Aaron G.
    Qureshi, Huma
    Mahmood, Hassan
    Hamid, Saeed
    Davies, Charlotte F.
    Trickey, Adam
    Glass, Nancy
    Saeed, Quaid
    Fraser, Hannah
    Walker, Josephine G.
    Mukandavire, Christinah
    Hickman, Matthew
    Martin, Natasha K.
    May, Margaret T.
    Averhoff, Francisco
    Vickerman, Peter
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2018, 47 (02) : 550 - 560
  • [33] Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
    Mullhaupt, Beat
    Bruggmann, Philip
    Bihl, Florian
    Blach, Sarah
    Lavanchy, Daniel
    Razavi, Homie
    Scott, Sarah Robbins
    Semela, David
    Negro, Francesco
    PLOS ONE, 2018, 13 (12):
  • [34] Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study
    Razavi, Homie
    Robbins, Sarah
    Zeuzem, Stefan
    Negro, Francesco
    Buti, Maria
    Duberg, Ann-Sofi
    Roudot-Thoraval, Francoise
    Craxi, Antonio
    Manns, Michael
    Marinho, Rui T.
    Hunyady, Bela
    Colombo, Massimo
    Aleman, Soo
    Antonov, Krasimir
    Arkkila, Perttu
    Athanasakis, Kostas
    Blach, Sarah
    Blachier, Martin
    Blasco, Antonio J.
    Calinas, Filipe
    Calleja, Jose L.
    Christensen, Peer B.
    Cramp, Matthew E.
    Croes, Esther
    de Knegt, Robert J.
    de Ledinghen, Victor
    Delile, Jean-Michel
    Estes, Chris
    Falconer, Karolin
    Farkkila, Martti
    Flisiak, Robert
    Frankova, Sona
    Gamkrelidze, Ivane
    Garcia-Samaniego, Javier
    Genov, Jordan
    Gerstoft, Jan
    Gheorghe, Liana
    Goldis, Adrian
    Gountas, Ilias
    Gregorcic, Sergeja
    Gschwantler, Michael
    Gunter, Jessie
    Halota, Waldemar
    Harcouet, Laura
    Hezode, Christophe
    Hoffmann, Patrick
    Horvath, Gabor
    Hrstic, Irena
    Jarcuska, Peter
    Jelev, Deian
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (05): : 325 - 336
  • [35] Hepatitis C: From diagnosis to global virus elimination
    Schmitt, Annika
    Sarrazin, Christoph
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (16) : 955 - 961
  • [36] Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs
    Sulkowski, Mark S.
    Martinez, Anthony
    Tyson, Gia L.
    Scholz, Kathleen
    Franco, Ricardo A.
    Kohli, Anita
    Julius, Susan F.
    Deming, Paulina
    Fink, Scott A.
    Lynch, Keisa
    Roytman, Marina
    Stainbrook, Tuesdae R.
    Turner, Marshe D.
    Viera-Briggs, Matthew
    Ramers, Christian B.
    JOURNAL OF VIRAL HEPATITIS, 2024, 31 (06) : 342 - 356
  • [37] The Role of Nonprofit and Nongovernmental Organizations and People With Viral Hepatitis on the Path Toward Hepatitis C Virus Elimination
    Adda, Danjuma
    James, Cary
    Peck, Raquel
    Ali, Mohammad
    Tiwana, Tajinder
    Kolawole, Tobiloba
    Wang, Su
    JOURNAL OF INFECTIOUS DISEASES, 2023, 228 : S154 - S159
  • [38] Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination
    Soipe, A. I.
    Razavi, H.
    Razavi-Shearer, D.
    Galarraga, O.
    Taylor, L. E.
    Marshall, B. D. L.
    EPIDEMIOLOGY AND INFECTION, 2016, 144 (16) : 3376 - 3386
  • [39] Barriers to Treatment of Hepatitis C Virus in the Direct-Acting Antiviral Era
    Ramers, Christian B.
    Liu, Jie
    Frenette, Catherine
    CURRENT TREATMENT OPTIONS IN INFECTIOUS DISEASES, 2019, 11 (02) : 92 - 102